Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1. / Christensen, Anne Francke; Le, Han; Kirchmann, Malene; Olesen, Jes.

I: Journal of Headache and Pain, Bind 13, Nr. 1, 2012, s. 21-7.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Christensen, AF, Le, H, Kirchmann, M & Olesen, J 2012, 'Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1', Journal of Headache and Pain, bind 13, nr. 1, s. 21-7. https://doi.org/10.1007/s10194-011-0386-5

APA

Christensen, A. F., Le, H., Kirchmann, M., & Olesen, J. (2012). Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1. Journal of Headache and Pain, 13(1), 21-7. https://doi.org/10.1007/s10194-011-0386-5

Vancouver

Christensen AF, Le H, Kirchmann M, Olesen J. Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1. Journal of Headache and Pain. 2012;13(1):21-7. https://doi.org/10.1007/s10194-011-0386-5

Author

Christensen, Anne Francke ; Le, Han ; Kirchmann, Malene ; Olesen, Jes. / Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1. I: Journal of Headache and Pain. 2012 ; Bind 13, Nr. 1. s. 21-7.

Bibtex

@article{35a0394ff8aa4fc9afe1e6e240b8b94e,
title = "Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1",
abstract = "A large two-stage GWAS by Antilla et al. reported the minor allele of rs1835740 on 8q22.1 to be associated with common types of migraine. The objective of the present study was to determine the clinical correlate of the variant in migraine without aura (MO). Clinical data on 339 successfully genotyped MO patients (patients with attacks of migraine without aura and no attacks of migraine with aura) were obtained by an extensive validated semi-structured telephone interview performed by a physician or a trained senior medical student. Reliable, systematic and extensive data on symptoms, age of onset, attack frequencies and duration, relevant comorbidity, specific provoking factors including different hormonal factors in females, and effect and use of medication, both abortive and prophylactic, were thereby obtained. A comparison of carriers and non-carriers were performed. Comparison of homozygotes with heterozygotes was not performed as the number of homozygotes was too small for statistical purposes. Data from other MO populations in the GWAS by Antilla et al. were not included as phenotype and clinical data were obtained differently. While thousands of patients are needed to detect a genetic variant like rs1835740, 339 are sufficient to detect meaningful clinical differences. 136 of 339 patients were carriers of the variant, 15 were homozygous. Comparison of carriers with non-carriers showed no significant difference in any of the parameters studied. In conclusion, the rs1835740 variant has no significant influence on the clinical expression of MO.",
author = "Christensen, {Anne Francke} and Han Le and Malene Kirchmann and Jes Olesen",
year = "2012",
doi = "10.1007/s10194-011-0386-5",
language = "English",
volume = "13",
pages = "21--7",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1

AU - Christensen, Anne Francke

AU - Le, Han

AU - Kirchmann, Malene

AU - Olesen, Jes

PY - 2012

Y1 - 2012

N2 - A large two-stage GWAS by Antilla et al. reported the minor allele of rs1835740 on 8q22.1 to be associated with common types of migraine. The objective of the present study was to determine the clinical correlate of the variant in migraine without aura (MO). Clinical data on 339 successfully genotyped MO patients (patients with attacks of migraine without aura and no attacks of migraine with aura) were obtained by an extensive validated semi-structured telephone interview performed by a physician or a trained senior medical student. Reliable, systematic and extensive data on symptoms, age of onset, attack frequencies and duration, relevant comorbidity, specific provoking factors including different hormonal factors in females, and effect and use of medication, both abortive and prophylactic, were thereby obtained. A comparison of carriers and non-carriers were performed. Comparison of homozygotes with heterozygotes was not performed as the number of homozygotes was too small for statistical purposes. Data from other MO populations in the GWAS by Antilla et al. were not included as phenotype and clinical data were obtained differently. While thousands of patients are needed to detect a genetic variant like rs1835740, 339 are sufficient to detect meaningful clinical differences. 136 of 339 patients were carriers of the variant, 15 were homozygous. Comparison of carriers with non-carriers showed no significant difference in any of the parameters studied. In conclusion, the rs1835740 variant has no significant influence on the clinical expression of MO.

AB - A large two-stage GWAS by Antilla et al. reported the minor allele of rs1835740 on 8q22.1 to be associated with common types of migraine. The objective of the present study was to determine the clinical correlate of the variant in migraine without aura (MO). Clinical data on 339 successfully genotyped MO patients (patients with attacks of migraine without aura and no attacks of migraine with aura) were obtained by an extensive validated semi-structured telephone interview performed by a physician or a trained senior medical student. Reliable, systematic and extensive data on symptoms, age of onset, attack frequencies and duration, relevant comorbidity, specific provoking factors including different hormonal factors in females, and effect and use of medication, both abortive and prophylactic, were thereby obtained. A comparison of carriers and non-carriers were performed. Comparison of homozygotes with heterozygotes was not performed as the number of homozygotes was too small for statistical purposes. Data from other MO populations in the GWAS by Antilla et al. were not included as phenotype and clinical data were obtained differently. While thousands of patients are needed to detect a genetic variant like rs1835740, 339 are sufficient to detect meaningful clinical differences. 136 of 339 patients were carriers of the variant, 15 were homozygous. Comparison of carriers with non-carriers showed no significant difference in any of the parameters studied. In conclusion, the rs1835740 variant has no significant influence on the clinical expression of MO.

U2 - 10.1007/s10194-011-0386-5

DO - 10.1007/s10194-011-0386-5

M3 - Journal article

C2 - 21964821

VL - 13

SP - 21

EP - 27

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 1

ER -

ID: 40186631